Member Info for PCS1954

Morning paulus47

Good to see you still posting and trust you are well.

I do chuckle how any slightly “positive “ narrative is jumped on immediately by certain people and even more amusing, how any damning post of Sareum, it’s BoD or even SOG’s posts gets the obligatory “5”recommendations within minutes of posting, even when posted at obscure times e.g Unite on Saturday evening ( apparently was selling out a couple of years ago) - little cartel of accounts me thinks!!

Anyway, I think we may be reaching a pivotal point as we approach the end of Q1, as I’ve said intrigued by various “nuances” since the move to Toxicity Studies and I’m sure SRA737 still has a play - may even see some “blue” for a change!

To the naysayers please don’t splutter in your coffee, it’s only an opinion- to those with a genuine interest in Sareum who “dyor”, have a good week!

GLA

Hi SOG

“What i do find a tad annoying is that when deciding to undertake these adittional toxicology studies, why the Bod did not decide to have 1801 compound made in good time in preparation for study start.”

Just my thoughts, they may have needed the confirmation of the fund raise before making the commitment to the toxicity studies due to the annual cash flow prediction ( penny to a pound, enter the usual cry from the nays “cut their salaries, out with Parker” ), then the obvious time factor in the preliminaries of getting underway - for instance, one assumes the CRO is UK, is it? - could be European or even global!

I’m comfortable it’s coming together, YoungJev, Damien and yourself added a breath of fresh air to the bb imo with your posts of last night and today discussing Sareum the “Business”, so thanks and Meg thank you for the amusement!

Finally, I have no embarrassment in defending the BoD for what there trying to achieve in the drug development world - I would be embarrassed though trying to be influential and posting “financial rhetoric” about the performance and outlook of the company, whilst openly admitting that I called it wrong previously because I was greedy!

Anyway as I’ve said, time will tell and I believe the clock is ticking Tick Tock!

GLA

Morning Smart_Inv

Given as I found yesterday, that the bb now comes with a caveat that any “bullish narrative” it will be questioned by the Oracle himself, I will try and be objective and trust not considered a sanctimunious (sic!) brother, but then again you never know where the gremlins are and their narrative!

Considering where Sareum are, perhaps any buying by BoD would hint at no discussions ongoing, I would like to be allowed to think we are, given we are unclear if Toxicity Studies are being backed and the return of SRA737 to CPF imminent (may already have been as “within 3 months”) - the BoD damned if they do, damned if they don’t - agree no buying is frustrating, but, I would prefer the former scenario if indeed that is the case - time will tell, and as Damion posted, we could we’ll be in RNS country very soon

GLA

Thanks for that info Damion.

GLA

Hi SOG

Yes, someone else who attended the AGM commented to me the same, which leaves me to believe that is why we await start date and as stated would like to think the complete drug compound is “fresh” rather than a botched together batch, even if it means a slight delay.

Of course, that opens up for criticism of the BoD by some but surely we would want the BoD to give this 110% and I’m sure JR will and if we roll over into Q3 so be it!

GLA

Potnak just recommended your post mate as laid up in bed and needed a laugh - it certainly did!

What did you do, put my post in Gemini and ask it to provide a reply using as many of my words as possible!

Not condescending, certainly not a criticism perhaps more an observation of you as you’ve kindly taken upon yourself to give one of me.

Using the word ``I'' frequently can reveal several psychological and social traits about an individual: Self-Focus: A high frequency of ``I'' may indicate a self-centered perspective, suggesting that the person is primarily focused on their own experiences and feelings.

No need for a RSVP as I’m sure you will!!

GLA

Hi Potnak

It was a generic post, which you appear to have taken personally can’t think why as it was just a surmise of the “blinking” obvious - also, as you’re not privy to my discussions with the BoD at AGM’s you may be just repeating some of my comments to them.

Try and chill man, a strange attitude to a supposedly intelligent man!

I’ve now left the meeting.

GLA

No one has lost any money until they’ve sold, hence, many a naysayer is still here because they’re frightened to let go in their broadcasted statements- how many have lambasted SP since consolidation, MHRA, RF (all under TM as Exec. Chairman of the BoD) but remain and still harp on about it, whoever comes in has same business structure to deal with.

I’ve had my moans as well as positive discussions with the BoD face to face at AGM’s, but, I balance it up and I’m here for the reasons mentioned in YoungDev’s posting this morning and with a fair wind I believe we will see change and be in a better place regarding sp - if not, only myself to blame, I bought the shares!

Yes, Sareum do have money to progress to P2 ready (the plan) if toxicity studies good (so science very important, much to the ignorance of some) and the company will be in a position to make judgements on it’s next move as a drug development company, potentially many alternatives from buy out to a raise if wishing to continue alone with many others in between.

As a shareholder, you can make a decision now, tomorrow or in the future - remember it was you who bought the shares and if you don’t believe in market manipulation, please explain how the likes of BlackRock and RiverFort exist.

Back to my day, and please dyor.

GLA

Hi SOG & Potnak

Good to see some “joined up” thinking between our posts.

I’d hazard a guess and say the CRO has been selected as you need a delivery address for drug compound and/or species. I’d also expect an order of drug compound that is “fresh” for the complete study and no risk of shelf life expiry given what’s at stake - I’m sure JR will take the lead on this!

GLA

Morning Shepster, good to hear from you and hope you’re well.

It is what it is, lots of conjecture as usual, is SRA737 returned as a dead duck or will there be a curve ball, has a CRO been selected, have sufficient drugs been manufactured and delivered for duration of study, etc.. I’m sure we will hear news when there is news and hopefully it’s very positive news.

As previously mentioned I’m intrigued by many of the nuances that have come into play in recent times and still have a half full glass, mind you, it could do with a top up!!

GLA

I’m as surprised as anybody that Clive Birch has not been heard from in his new role in the BoD reshuffle.

That said and only my thoughts is that SP is overseeing all commercial matters at this moment in time, which given SRA737 comes back to CPF in 7 weeks or less, Toxicity Studies due to start, I believe there must soon be a release of news - also, as per some and posted by me previously, “deals” can come at any time and “we’ve been advised” can be a censored alternative to “we’ve been asked “ or even “we’ve been told” - dyor!

GLA

Interesting if nothing else!

https://www.fiercebiotech.com/biotech/bristol-myers-backs-out-dupixent-fight-axing-allergy-asset-despite-phase-3-win

GLA

I have no problem with Reality10’s views, all very articulate with reasoning, but, like a few others on here all based on a placement for future funding - if Sareum progress in Toxicity Studies positively in the 16 weeks I’m sure other “equity” options will come into play - there’s many a JV or VC out there looking for such an opportunity - just a thought!

GLA

And of course we’ve all gone through our lives without changing our intended plans - yeah right!

I believe the BoD have seen a potentially better alternative to their stated pathway and taken it as it may get us bought out sooner or alternatively provide a pathway for some of the loftier valuations being mentioned by some!

A strange mix of posts today, hopefully, people want Sareum aka TM, JR and SP to succeed!!

GLA

Hi Aber

Just as a consideration, maybe the BoD were in discussion with a third party as whether to continue with P1b as previously indicated and/or proceed to P2 trial ready during Q3, who knows - but, I don’t believe they just sat around!

I appreciate the frustrations ( I have them myself ), but, the last thing we need now is a FU due to the pleasing of shareholders impatience.

GLA

Hi SOG

I concur with Aber, you provide a fantastic insight to the bb but seem to want to fight with anything negative - can’t deny I didn’t do similar in the past and learnt my lesson, can’t change people’s opinions so no longer waste my time on such .

FWIW, I note there is an impatience here again and yes I would like to see more urgency, that said, I also realise that we are at the critical point of why we invested and I personally can accept that timelines are more likely to drift than improve, but, also know the BoD want this as much as us and that’s key for me.

I get that they are on high salaries but if they deliver who cares, if they don’t their share options are worthless like our shares, hopefully they deliver but that’s our risk v reward whilst we bicker on our keyboards!

There’s lots of criteria to enable commencement of next studies from selection of CRO, provision of the test species and sufficient supply of drug to carry out studies, none of which are readily available on the shelf waiting for Sareum and once chosen/selected/delivered need to be coordinated to commence the trial - look at life in general, very little gets done on time and I trust both TM and JR to ensure we go into these trials with the best possible chance of success.

If people want to negate and/or belittle above fine, there’s not much I can do about that, after all, it’s just an opinion!

GLA

Totally concur Potnak with the overall timelines you state and of course with the proviso that the Toxicity Studies progress in the manner we believe and indicated by the BoD.

The only thing I would add is we don’t know what is going on in the background on the future finance structure and maybe something comes into play during this period - looking at most recent biotech deals (if indeed the BoD are seeking such) they have happened out of the blue without much publicity, so who knows!

GLA

Ps BB meant to say apologies!

Hi HBD

Many thanks, you have the job as PA, I was just about to post the full script with reservations as I know some on the bb do have an affliction to “cut and paste” information!!

GLA

….. from a fellow shareholder to me!

https://www.fiercebiotech.com/biotech/takeda-tightens-reins-early-stage-investments-looks-expand-option-deals-rd-head.

GLA